148 related articles for article (PubMed ID: 34853223)
1. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
3. Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.
Kraigher-Krainer E; Shah AM; Gupta DK; Santos A; Claggett B; Pieske B; Zile MR; Voors AA; Lefkowitz MP; Packer M; McMurray JJ; Solomon SD;
J Am Coll Cardiol; 2014 Feb; 63(5):447-56. PubMed ID: 24184245
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
5. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
6. Associations between left ventricular diastolic function and right ventricular function in patients with and without preserved left ventricular ejection fraction.
Oki T; Tanaka H; Imanishi T; Nakamachi Y; Saegusa J; Kawano S; Hirata KI; Nishimura Y
J Echocardiogr; 2018 Jun; 16(2):81-86. PubMed ID: 29230641
[TBL] [Abstract][Full Text] [Related]
7. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
[TBL] [Abstract][Full Text] [Related]
8. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
9. Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
Furuya-Kanamori L; Doi SA; Onitilo A; Akhtar S
Expert Opin Drug Saf; 2020 Feb; 19(2):223-228. PubMed ID: 31698959
[No Abstract] [Full Text] [Related]
10. Evaluation of elevated left ventricular end diastolic pressure in patients with preserved ejection fraction using cardiac magnetic resonance.
Gao C; Tao Y; Pan J; Shen C; Zhang J; Xia Z; Wan Q; Wu H; Gao Y; Shen H; Lu Z; Wei M
Eur Radiol; 2019 May; 29(5):2360-2368. PubMed ID: 30631923
[TBL] [Abstract][Full Text] [Related]
11. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
12. Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.
Dobbin SJH; Cameron AC; Petrie MC; Jones RJ; Touyz RM; Lang NN
Heart; 2018 Dec; 104(24):1995-2002. PubMed ID: 30228246
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
Sobu R; Numakura K; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2023 Feb; 12(4):4100-4109. PubMed ID: 36200612
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Schutz FA; Je Y; Richards CJ; Choueiri TK
J Clin Oncol; 2012 Mar; 30(8):871-7. PubMed ID: 22312105
[TBL] [Abstract][Full Text] [Related]
15. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Accuracy of Tissue Doppler Index E/e' for Evaluating Left Ventricular Filling Pressure and Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Sharifov OF; Schiros CG; Aban I; Denney TS; Gupta H
J Am Heart Assoc; 2016 Jan; 5(1):. PubMed ID: 26811160
[TBL] [Abstract][Full Text] [Related]
17. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.
Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients.
Liu B; Ding F; Liu Y; Xiong G; Lin T; He D; Zhang Y; Zhang D; Wei G
Oncotarget; 2016 Oct; 7(41):67661-67673. PubMed ID: 27602778
[TBL] [Abstract][Full Text] [Related]
19. Association of Diastolic Dysfunction with N-terminal Pro-B-type Natriuretic Peptide Level in Heart Failure Patients with Preserved Ejection Fraction.
Islam MN; Chowdhury MS; Paul GK; Debnath RC; Shakil SS
Mymensingh Med J; 2019 Apr; 28(2):333-346. PubMed ID: 31086148
[TBL] [Abstract][Full Text] [Related]
20. Rationale and Design of the Multicenter Trial on Japan Working Group on the Effects of Angiotensin Receptor Blockers Selection (Azilsartan vs. Candesartan) on Diastolic Function in the Patients Suffering from Heart Failure with Preserved Ejection Fraction: J-TASTE Trial.
Takahama H; Asakura M; Abe Y; Ajioka M; Aonuma K; Anzai T; Hayashi T; Hiramitsu S; Kawai H; Kioka H; Kimura K; Lim YJ; Matsuoka K; Motoki H; Nagata Y; Nakamura S; Ohte N; Ozaki Y; Sasaoka T; Tamaki S; Hamasaki T; Kitakaze M;
Cardiovasc Drugs Ther; 2018 Aug; 32(4):381-388. PubMed ID: 29974299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
